-
公开(公告)号：US08334373B2
公开(公告)日：2012-12-18
申请号：US13038672
申请日：2011-03-02
申请人： Hans-Peter Vornlocher , Ingo Roehl , Philipp Hadwiger , Tracy Stage Zimmermann , Muthiah Manoharan , Kallanthottathil G. Rajeev , Akin Akinc
发明人： Hans-Peter Vornlocher , Ingo Roehl , Philipp Hadwiger , Tracy Stage Zimmermann , Muthiah Manoharan , Kallanthottathil G. Rajeev , Akin Akinc
CPC分类号： C07H21/02 , C12N15/111 , C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/318 , C12N2310/321 , C12N2310/322 , C12N2310/323 , C12N2310/3231 , C12N2310/53 , C12N2320/51 , C12N2310/3521 , C12N2310/3525 , C12N2310/3527
摘要： This invention relates to modified double-stranded oligoribonucleic acid (dsRNA) having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene.
摘要翻译： 本发明涉及在细胞和生物流体中具有改善的稳定性的修饰的双链寡核糖核酸（dsRNA），以及制备和鉴定具有改善的稳定性的dsRNA的方法，以及使用dsRNA抑制靶基因的表达或功能。
-
公开(公告)号：US08293719B2
公开(公告)日：2012-10-23
申请号：US13043228
申请日：2011-03-08
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 所述化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
公开(公告)号：US20120252872A1
公开(公告)日：2012-10-04
申请号：US13450886
申请日：2012-04-19
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/718 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节载脂蛋白B的表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸下载载脂蛋白B的方法。
-
公开(公告)号：US08188061B2
公开(公告)日：2012-05-29
申请号：US12728139
申请日：2010-03-19
CPC分类号： C12N15/113 , A61K31/7105 , A61K31/718 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节载脂蛋白B的表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸下载载脂蛋白B的方法。
-
公开(公告)号：US07994307B2
公开(公告)日：2011-08-09
申请号：US12510128
申请日：2009-07-27
CPC分类号： C12N15/1135 , C12N2310/14 , C12N2310/315 , C12N2310/32 , C12N2310/33
摘要： The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节Bcr-Abl表达的组合物和方法，更具体地涉及通过RNA干扰的寡核苷酸（例如化学修饰的寡核苷酸）对Bcr-Abl mRNA和Bcr-Abl蛋白水平的下调。
-
66.发明申请公开(公告)号：US20110124711A1
公开(公告)日：2011-05-26
申请号：US13016896
申请日：2011-01-28
申请人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
发明人： Dinah Sah , Maria Frank-Kamenetsky , Anke Geick , Philipp Hadwiger , Ingo Roehl , Pamela Tan , Hans-Peter Vornlocher
CPC分类号： C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene in a cell.
摘要翻译： 本发明涉及用于抑制Nav1.8基因（Nav1.8基因）表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的反义链，其基本上 与Nav1.8基因的至少一部分互补。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于治疗由使用该药物组合物的Nav1.8基因表达引起的疾病的方法; 以及抑制细胞中Nav1.8基因表达的方法。
-
公开(公告)号：US07919473B2
公开(公告)日：2011-04-05
申请号：US11340080
申请日：2006-01-25
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
68.发明授权公开(公告)号：US07473525B2
公开(公告)日：2009-01-06
申请号：US10384260
申请日：2003-03-07
申请人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
发明人： Roland Kreutzer , Stefan Limmer , Hans-Peter Vornlocher , Philipp Hadwiger , Anke Geick , Matthias Ocker , Christoph Herold , Detlef Schuppan
CPC分类号： C12N15/113 , C12N15/1131 , C12N2310/152 , C12N2310/315 , C12N2310/3183 , C12N2310/33 , C12N2310/351 , C12N2310/3511 , C12N2310/53
摘要： The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising a complementary RNA strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially identical to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
摘要翻译： 本发明涉及用于抑制抗凋亡基因表达的双链核糖核酸（dsRNA），其包含具有长度小于25个核苷酸的核苷酸序列的互补RNA链，其至少与至少 凋亡基因的一部分，如Bcl基因。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 用于使用该药物组合物治疗由抗凋亡基因表达引起的疾病的方法; 以及抑制细胞中抗凋亡基因表达的方法。
-
公开(公告)号：US20080233584A1
公开(公告)日：2008-09-25
申请号：US12038808
申请日：2008-02-27
CPC分类号： C12N15/1135 , C12N2310/14
摘要： The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
摘要翻译： 本发明涉及用于调节MLL-AF4融合基因表达的组合物和方法，更具体地涉及通过化学修饰的寡核苷酸对MLL-AF4的下调。
-
70.发明授权公开(公告)号：US07320965B2
公开(公告)日：2008-01-22
申请号：US11588674
申请日：2006-10-27
申请人： Dinah Wen-Yee Sah , Philipp Hadwiger , Ingo Roehl , Birgit Bramlage , Pamela Tan , Hans-Peter Vornlocher , David Bumcrot
发明人： Dinah Wen-Yee Sah , Philipp Hadwiger , Ingo Roehl , Birgit Bramlage , Pamela Tan , Hans-Peter Vornlocher , David Bumcrot
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
摘要翻译： 本发明涉及用于抑制亨廷顿蛋白基因（HD基因）表达的双链核糖核酸（dsRNA），其包含长度小于25个核苷酸的核苷酸序列的反义链，并且至少与至少 HD基因的一部分。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物; 使用该药物组合物治疗由HD基因的表达引起的疾病或其突变形式的方法; 以及抑制细胞中亨廷顿蛋白基因表达的方法。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.052 秒)
